Bivatuzumab mertansine

Revision as of 20:19, 27 September 2011 by WikiBot (talk | contribs) (Protected "Bivatuzumab mertansine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Template:Drugbox-mab

WikiDoc Resources for Bivatuzumab mertansine

Articles

Most recent articles on Bivatuzumab mertansine

Most cited articles on Bivatuzumab mertansine

Review articles on Bivatuzumab mertansine

Articles on Bivatuzumab mertansine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bivatuzumab mertansine

Images of Bivatuzumab mertansine

Photos of Bivatuzumab mertansine

Podcasts & MP3s on Bivatuzumab mertansine

Videos on Bivatuzumab mertansine

Evidence Based Medicine

Cochrane Collaboration on Bivatuzumab mertansine

Bandolier on Bivatuzumab mertansine

TRIP on Bivatuzumab mertansine

Clinical Trials

Ongoing Trials on Bivatuzumab mertansine at Clinical Trials.gov

Trial results on Bivatuzumab mertansine

Clinical Trials on Bivatuzumab mertansine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bivatuzumab mertansine

NICE Guidance on Bivatuzumab mertansine

NHS PRODIGY Guidance

FDA on Bivatuzumab mertansine

CDC on Bivatuzumab mertansine

Books

Books on Bivatuzumab mertansine

News

Bivatuzumab mertansine in the news

Be alerted to news on Bivatuzumab mertansine

News trends on Bivatuzumab mertansine

Commentary

Blogs on Bivatuzumab mertansine

Definitions

Definitions of Bivatuzumab mertansine

Patient Resources / Community

Patient resources on Bivatuzumab mertansine

Discussion groups on Bivatuzumab mertansine

Patient Handouts on Bivatuzumab mertansine

Directions to Hospitals Treating Bivatuzumab mertansine

Risk calculators and risk factors for Bivatuzumab mertansine

Healthcare Provider Resources

Symptoms of Bivatuzumab mertansine

Causes & Risk Factors for Bivatuzumab mertansine

Diagnostic studies for Bivatuzumab mertansine

Treatment of Bivatuzumab mertansine

Continuing Medical Education (CME)

CME Programs on Bivatuzumab mertansine

International

Bivatuzumab mertansine en Espanol

Bivatuzumab mertansine en Francais

Business

Bivatuzumab mertansine in the Marketplace

Patents on Bivatuzumab mertansine

Experimental / Informatics

List of terms related to Bivatuzumab mertansine

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Bivatuzumab mertansine is a humanized monoclonal antibody and which it's used to treat squamous cancer. It has a chelator, mertansine.

Template:Humanizedmonoclonals Template:SIB

Template:WS